A Slippery Slope to Human Germline Modification
By Marcy Darnovsky,
Nature
| 07. 09. 2013
The UK government’s recent move towards human trials of mitochondrial-replacement techniques has prompted intense interest among scientists and bioethicists, while the media continue to frame mitochondrial replacement as a matter of ‘three-parent babies’. The description is accurate — it would involve a woman affected by mitochondrial disease, whose egg provides a nucleus, a second woman to provide a ‘healthy’ egg and a man to provide sperm — but this simple framing overshadows profound social and ethical concerns.
Mitochondrial-replacement procedures would constitute germline modification. Were the United Kingdom to grant a regulatory go-ahead, it would unilaterally cross a legal and ethical line on this issue that has been observed by the entire international community. This consensus holds that genetic-engineering tools may be applied, with appropriate care and safeguards, to treat an individual’s medical condition, but should not be used to modify gametes or early embryos and so manipulate the characteristics of future children.
Supporters argue that these concerns do not apply to modifications of mitochondrial DNA, which they characterize as an insignificant part of the human genome that does not affect...
Related Articles
By Emma McDonald Kennedy
| 09.25.2025
In the leadup to the 2024 election, Donald Trump repeatedly promised to make IVF more accessible. He made the commitment central to his campaign, even referring to himself as the “father of IVF.” In his first month in office, Trump issued an executive order promising to expand IVF access. The order set a 90-day deadline for policy recommendations for “lowering costs and reducing barriers to IVF,” although it didn’t make any substantive reproductive healthcare policy changes.
The response to the...
Sir Francis Galton, 1890s, by Eveleen Myers (née Tennant)
npg.org
Public Domain via Wikipedia
As has been discussed in recent issues of Biopolitical Times (1, 2), there are, increasingly, companies that claim to be selling parents better babies by selecting the “best” embryos. These services don’t come cheap – think $50,000, or even more, for embryo testing, plus perhaps as much again for IVF and concomitant services. To most of us, that is extremely expensive...
By Margaux MacColl, The San Francisco Standard | 09.17.2025
Designer babies are coming soon to an IVF clinic near you.
Nucleus Genomics, founded by Kian Sadeghi in 2020, when he was just 20, got its start analyzing genomes to weigh a person’s risk of everything from cancer to ADHD...
By Marianne Lamers, NEMO Kennislink [cites CGS' Katie Hasson] | 09.23.2025
Een rijtje gespreide vulva’s gaapt de bezoeker aan. Zó ziet een bevalling eruit, en zó een baarmoeder met foetus. Een zwangerschap, maar dan zonder zwangere vrouw, gestript van zorgen, gêne en pijn. De zwangerschapsmodellen en oefenbekkens, te zien in de...